ArticleMaterials today. Bio2026
The mechanistic study of injectable hydrogel loaded with BMSC-exosomes in regulating the TGF-β/MMP axis to inhibit experimental myopia model.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioelectronic interfaces for restoring vision pathways.Materials today. Bio · 2026Review
- Hypoxia-induced OPN5 expression is associated with matrix-preserving responses in human scleral fibroblasts.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological myopia involves reduced collagen deposition and scleral thinning, leading to axial elongation-a process exacerbated by chronic inflammation that disrupts scleral extracellular matrix homeostasis. To address this, we developed an injectable microgel system based on methacrylated alginate (AlgMA) loaded with BMSC-derived exosomes for preventing myopia progression. The photocrosslinkable AlgMA hydrogel exhibited a compressive modulus of ∼10 kPa, providing mechanical support for scleral reinforcement, while its porous network facilitated sustained exosome release. Processing into microgels (AlgMA-MGs) via repeated extrusion through a 25-gauge needle significantly improved injectability of AlgMA hydrogel. Exosome-loaded AlgMA-MGs (Exos-AlgMA-MGs) enhanced fibroblast proliferation and migration, downregulated MMP-2, and upregulated collagen I synthesis via modulation of the TGF-β/MMP axis. In a guinea pig form-deprivation model, both AlgMA-MGs and Exos-AlgMA-MGs attenuated axial elongation in myopic eyes, with the Exos-AlgMA-MGs showing optimal efficacy over four weeks, attributable to the combined biomechanical and bioactive effects. Histological analysis further confirmed that Exos-AlgMA-MGs increased scleral thickness and downregulated the expression of inflammatory factors in myopic eyes, thereby achieving effective anti-scleral remodeling. These findings suggest that Exos-AlgMA-MGs represents a promising strategy for controlling myopia progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.